Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine.

ABSTRACT:

Background

The four co-circulating and immunologically interactive dengue virus serotypes (DENV1-4) pose a unique challenge to vaccine design because sub-protective immunity can increase the risk of severe dengue disease. Existing dengue vaccines have lower efficacy in DENV seronegative individuals but higher efficacy in DENV exposed individuals. There is an urgent need to identify immunological measures that are strongly associated with protection against viral replication and disease following sequential exposure to distinct serotypes.

Methods/design

This is a phase 1 trial wherein healthy adults with neutralizing antibodies to zero (seronegative), one non-DENV3 (heterotypic), or more than one (polytypic) DENV serotype will be vaccinated with the live attenuated DENV3 mono

SUBMITTER: Odio CD 

PROVIDER: S-EPMC10204028 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature